Biogen (BIIB) PT Slashed to $320 at Truist Securities on Lower COGS, Maintained at Buy, Focus Remains on lecanemab
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas lowered the price target on Biogen (NASDAQ: BIIB) to $320.00 (from $343.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
